IP Library Patent Application 17068441
Patent Application
App. No. 17/068,441

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/068,441
Abstract

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Claims (15)

1 .- 27 . (canceled)

28 . A heterodimeric protein comprising:

a) first monomer comprising a first human antibody heavy chain constant domain that is a variant human antibody heavy chain constant domain comprising one or more amino acid substitutions selected from the following amino acid substitutions: G137E, G138S, S192N, L193F, I199T, N203D, K214T, K222T, 221-225 DKTHT to VE, H268Q, K274Q, R355Q, N384S, K392N, V397M, Q419E, and K447del, according to EU numbering; and

b) a second monomer comprising a second human antibody heavy chain constant domain.

29 . A heterodimeric protein comprising:

a) a first monomer comprising a first human antibody heavy chain constant domain that is a variant human antibody heavy chain constant domain comprising amino acid substitutions selected from the following amino acid substations: Q196K, P217R, P228R, N276K and H435R, according to EU numbering; and

b) a second monomer comprising a second human antibody heavy chain constant domain.

30 . A heterodimeric protein according to claim 28 , wherein the amino acid substitutions of the first human antibody heavy chain constant domain comprises K274Q, R355Q, Q419E, and K447del.

31 . A heterodimeric protein according to claim 29 , wherein the amino acid substitutions of the first human antibody heavy chain constant domain comprises P217R, P228R, and N276K.

32 . A heterodimeric protein according to claim 29 , wherein the amino acid substitutions of the first human antibody heavy chain constant domain comprises Q196K and N276K.

33 . The heterodimeric protein according to claim 28 or 29 , wherein the second human antibody heavy chain constant domain is a wild type human antibody heavy chain constant domain.

34 . The heterodimeric protein according to claim 28 or 29 , wherein the second human antibody heavy chain constant domain is a variant human antibody heavy chain constant domain comprising amino acid modifications as compared to a wild type parent human antibody heavy chain constant domain.

35 . The heterodimeric protein according to claim 34 , wherein said first and second human antibody heavy chain constant domains further comprise amino acid substitutions 428L and 434S.

36 . The heterodimeric protein according to claim 28 or 29 , wherein the first and second human antibody heavy chain constant domains each comprise a CH 1 -hinge-CH 2 -CH 3 domain.

37 . The heterodimeric protein according to claim 28 or 29 , wherein the first and second human antibody heavy chain constant domains each comprise a CH 2 -CH 3 domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: BERNETT, MATTHEW J.; MOORE, GREGORY L.; DESJARLAIS, JOHN; RASHID, RUMANA
To: XENCOR, INC.
Reel/Frame 055581/0153 →